D.E. Shaw & Co
FOMX

D.E. Shaw & Co’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

D.E. Shaw & Co’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-21,880
Closed -$52K – 4127
2019
Q2 		$52K Sell
21,880
-1,979
-8% -$5.91K ﹤0.01% 3586
2019
Q1 		$89K Sell
23,859
-2,900
-11% -$10.9K ﹤0.01% 3485
2018
Q4 		$96K Sell
26,759
-199,251
-88% -$867K ﹤0.01% 3644
2018
Q3 		$1.3M Buy
226,010
+172,248
+320% +$985K ﹤0.01% 2509
2018
Q2 		$269K Buy
53,762
+7,336
+16% +$37.8K ﹤0.01% 3421
2018
Q1 		$238K Buy
46,426
+9,232
+25% +$55.6K ﹤0.01% 3251
2017
Q4 		$224K Buy
+37,194
New +$224K ﹤0.01% 3383
2017
Q3 		– Sell
-16,327
Closed -$76K – 3699
2017
Q2 		$76K Sell
16,327
-50,046
-75% -$223K ﹤0.01% 3284
2017
Q1 		$329K Buy
66,373
+23,327
+54% +$224K ﹤0.01% 2930
2016
Q4 		$478K Buy
43,046
+22,688
+111% +$213K ﹤0.01% 2881
2016
Q3 		$189K Sell
20,358
-32,043
-61% -$268K ﹤0.01% 3212
2016
Q2 		$333K Sell
52,401
-7,893
-13% -$52.4K ﹤0.01% 2986
2016
Q1 		$393K Buy
60,294
+5,906
+11% +$38.1K ﹤0.01% 2902
2015
Q4 		$441K Buy
54,388
+33,103
+156% +$247K ﹤0.01% 3156
2015
Q3 		$156K Sell
21,285
-20,754
-49% -$212K ﹤0.01% 3556
2015
Q2 		$431K Buy
+42,039
New +$465K ﹤0.01% 3243

Other funds holding FOMX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

D.E. Shaw & Co's FOMX Position: Q3 2019 in Review

D.E. Shaw & Co sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q3 2019, closing a stake of 21,880 shares — an estimated $52K sold.

D.E. Shaw & Co first reported a position in FOMX in Q2 2015 and held it in 16 quarters. The position peaked at $1.3M in Q3 2018. 59 funds tracked by Wall St. Rank hold FOMX as of Q3 2019.

  • D.E. Shaw & Co reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q3 2019 after selling out during the quarter.
  • D.E. Shaw & Co sold 21,880 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q3 2019, an estimated $52K.
  • D.E. Shaw & Co first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2015 and held it in 16 quarters.
  • D.E. Shaw & Co's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $1.3M in Q3 2018.
  • 59 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q3 2019.

Based on D.E. Shaw & Co's 13F filing for Q3 2019, filed 14 Nov 2019.